Penta has a special and longstanding collaboration with the MRC Clinical Trials Unit (CTU) at UCL. The MRC CTU at UCL is at the forefront of resolving internationally important questions in infections and cancer, and delivering swifter and more effective translation of scientific research into patient benefits. It does this by carrying out challenging and innovative studies, and developing and implementing methodological advances in study design, conduct and analysis.
The MRC CTU at UCL, together with the INSERM SC10 trials unit in Paris, developed and ran the first Penta trial investigating immediate or deferred zidovudine in children with HIV, which ran in parallel with Concorde, a similar trial in adults. The MRC CTU at UCL has contributed scientific leadership and undertaken the role of lead trials unit in no less than 10 Penta trials, the most recent being ODYSSEY (PENTA 20).
With a wider infections remit, similar to that of the PENTA-ID network, the MRC CTU at UCL is a partner in two new bacterial infections management trials in children, PediCAP and the NeoAMR program.
The MRC CTU at UCL also hosts the paediatric part of the European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC). EPPICC is a joint project between the MRC CTU at UCL and the Great Ormond Street Institute of Child Health, also at UCL, and undertakes individual patient meta-analyses of data from pregnancy and paediatric HIV cohorts across 15 countries in Europe, Russia, Ukraine and Thailand.
Current and past members of MRC CTU at UCL, Diana Gibb and Janet Darbyshire, were founding members of PENTA in 1991, along with Claude Griscelli, Marianne Debré and Carlo Giaquinto. Diana Gibb is currently a Penta Board member.